Genomics plc is an ambitious genome analytics business formed in March 2014 by four leading scientists at the University of Oxford, including Peter Donnelly (Director of the Wellcome Trust Centre for Human Genetics) and Gil McVean (Director of the Big Data Institute). The focus of the company is to use genomic data to understand human biology, and our vision is to bring together human genomic data linked to health and other outcomes, and develop sophisticated analytical methods for their interpretation in various scientific contexts. We have already developed the largest genotype-phenotype database of its kind in the world (comprising more than 1300 studies, 4 million participants and 1000 unique phenotypes), together with functional genomic data. Our collaborations in the health sector include several leading pharmaceutical companies, and we act as Analysis Partner for Genomics England's GENE Consortium – a group of large national and multinational companies seeking to use the data from the 100,000 Genomes Project to develop new diagnostics and treatments. Backed by some of the leading investors in life sciences, Genomics plc has a cross-disciplinary team of over 30 people, primarily scientists and software engineers, based in central Oxford.